Decision Benefits Medicaid Patients with Chronic Wounds
NEWPORT NEWS, Virginia (January 1, 2014) – Effective immediately, the Kentucky Department for Medicaid Services will provide coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds.
“We applaud the decision by the Kentucky Department of Medicaid Services to cover this limb and life-saving product for their nearly 800,000 Medicaid recipients,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Kentucky residents with diabetic and venous leg ulcers will now have access to cost-effective living cell therapy. Living cell therapy has been cited as the new standard of care for these types of ulcers.
Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.
About 20% of adults in Kentucky that are over 65 have Type 2 diabetes, a dramatic increase from 14% in 2000. The number of residents with Type 2 diabetes has grown to an estimated 370,000, with 24 lower leg amputations each week due to diabetes. Treating diabetics in Kentucky costs over $2 Billion a year. “We will work tirelessly with the medical institutions and practitioners in Kentucky to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.
TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and payers thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.
TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing.
Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.
For more information on TheraSkin coverage in Kentucky, please go to the Physician Fee Schedule located at http://chfs.ky.gov/dms/fee.htm to view the 2014 update.